Patents Examined by Timothy Thomas
  • Patent number: 10118900
    Abstract: The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: November 6, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark J. Macielag, Rui Zhang, Yue-Mei Zhang, Bin Zhu, Michael H. Parker, Donald W. Ludovici, Daniel J. Parks, Bart L. DeCorte, Michael N. Greco
  • Patent number: 9937183
    Abstract: Methods and compounds for treating, preventing, reducing the risk of and/or delaying the onset of a microbial infection in a subject are disclosed herein, wherein the microbial infection is caused by one or more microorganisms (e.g., one or more bacteria) which can be used as a biological weapon, such as Bacillus anthracis, Franciscella tularensis, Yersinia pestis, Burkholderia mallei, and Burkholderia pseudomallei. Also disclosed are pharmaceutical compositions or kits for treating, preventing, reducing the risk of and/or delaying the onset of a microbial infection.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: April 10, 2018
    Assignee: Melinta Therapeutics, Inc.
    Inventors: Zoltan F. Kanyo, Ashoke Bhattacharjee
  • Patent number: 9914720
    Abstract: The invention relates to crystalline forms of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone, processes for the preparation thereof, pharmaceutical compositions containing such crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as orexin receptor antagonists.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: March 13, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Markus Von Raumer, Jodi T. Williams
  • Patent number: 9901567
    Abstract: This invention relates to novel agents that are analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and their conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: February 27, 2018
    Assignee: Syntarga B.V.
    Inventors: Patrick Henry Beusker, Henri Johannes Spijker, Johannes Albertus Frederikus Joosten, Tijl Huijbregts, Franciscus Marinus Hendrikus De Groot
  • Patent number: 9889129
    Abstract: A method of modulating ribonucleotide reductase activity in a neoplastic cell includes administering to the cell an amount of a ribonucleotide reductase allosteric modulator (RRAmod), the amount being effective to inhibit neoplastic cell growth.
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: February 13, 2018
    Assignee: Case Western Reserve University
    Inventor: Chris Dealwis
  • Patent number: 9872914
    Abstract: This solid pharmaceutical composition is useful as a solid pharmaceutical composition of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol, which is excellently elutable and moldable and is stable in long-term storage, or a salt thereof.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: January 23, 2018
    Assignee: TOYAMA CHEMICAL CO., LTD.
    Inventors: Hiroyuki Inaba, Mitsuhiro Nagata
  • Patent number: 9872845
    Abstract: The invention provides a method of treating myeloma and lymphoma using a pharmaceutical composition containing a pharmaceutically acceptable diluent along with an ion pair formed by triethanolamine and a compound of Formula I:
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: January 23, 2018
    Assignee: Rafael Pharmaceuticals, Inc.
    Inventors: Robert G. L. Shorr, Robert J. Rodriguez, Rajinder Bhasin
  • Patent number: 9872820
    Abstract: Described are personal care, preferably skin care compositions, comprising polyolefin blends comprising at least one metallocene catalyzed polyolefin with a density above 0.90 g/cm3, at least one metallocene catalyzed polyolefin with a density equal to or below 0.90 g/cm3, provided that the average melt index for the polyolefin blend is greater than 7; and a cosmetically acceptable hydrocarbon oil, provided that the composition does not contain ethylene acrylic copolymer.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: January 23, 2018
    Assignees: Dow Global Technologies LLC, Rohm and Haas Company
    Inventors: Ying O'Connor, Curtis Schwartz, Qichun Wan, Thomas H. Peterson, Thomas P. Clark, John W. Kramer
  • Patent number: 9844558
    Abstract: This disclosure generally relates to methods for reducing the risk of preterm birth in a pregnant human female patient that include subcutaneous administration of HPC. The disclosure relates in part to the discovery that subcutaneous administration of HPC is actually feasible and can result in sufficient plasma levels of HPC in pregnant patients that can reduce the risk of preterm birth.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: December 19, 2017
    Assignee: AMAG Pharmaceuticals, Inc.
    Inventors: Robert Birch, Michael J. Jozwiakowski
  • Patent number: 9839691
    Abstract: Pharmaceutical formulations containing lipoic acid derivatives and ion pairs thereof are described. The pharmaceutical formulations are useful in the treatment of medical disorders, such as cancer.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: December 12, 2017
    Assignee: RAFAEL PHARMACEUTICALS, INC.
    Inventors: Robert G. L. Shorr, Robert J. Rodriguez, Rajinder Bhasin
  • Patent number: 9833446
    Abstract: A method for preventing, slowing, or blocking the formation of an exostosis or an enchondromas comprising administering to an animal in need thereof a hedgehog pathway inhibitor such as a Smoothened inhibitor.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: December 5, 2017
    Assignees: Rhode Island Hospital, University Health Network
    Inventors: Wentian Yang, Benjamin G. Neel
  • Patent number: 9827352
    Abstract: Fatty acid-based, pre-cure-derived biomaterials, methods of making the biomaterials, and methods of using them as drug delivery carriers are described. The fatty acid-derived biomaterials can be utilized alone or in combination with a medical device for the release and local delivery of one or more therapeutic agents. Methods of forming and tailoring the properties of said biomaterials and methods of using said biomaterials for treating injury in a mammal are also provided.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: November 28, 2017
    Assignee: Atrium Medical Corporation
    Inventors: Keith M. Faucher, Hui Tang, Paul Martakos, Theodore Karwoski, Allison Sullivan, Greg Melville, Scott E. Corbeil
  • Patent number: 9827353
    Abstract: Fatty acid-derived biomaterials, methods of making the biomaterials, and methods of using them as drug delivery carriers are described. The fatty acid-derived biomaterials can be utilized alone or in combination with a medical device for the release and local delivery of one or more therapeutic agents. Methods of forming and tailoring the properties of said biomaterials and methods of using said biomaterials for treating injury in a mammal are also provided.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: November 28, 2017
    Assignee: Atrium Medical Corporation
    Inventors: Keith M. Faucher, Hui Tang, Joseph Ferraro, Paul Martakos, Theodore Karwoski, Scott E. Corbeil
  • Patent number: 9815777
    Abstract: Metformin salts of 2,4-thiazolidinediones are described for the treatment of diabetes mellitus Type2, gestational diabetes, polycystic ovary syndrome, non-alcoholic fatty liver disease, coronary artery disease, pancreatic cancer, premature puberty, and other diseases which manifest insulin resistance.
    Type: Grant
    Filed: September 20, 2014
    Date of Patent: November 14, 2017
    Assignee: Jiva Pharma, Inc.
    Inventor: Om P Goel
  • Patent number: 9808435
    Abstract: The present invention is directed to antiviral compositions that provide efficacy against non-envelope viruses such as noroviruses. The antiviral compositions comprise an alkyl 2-hydroxycarboxylic acid and an effective amount of a sulfonated surfactant. The composition may be used as a topical on human skin, as a hand sanitizer or as a hard surface cleaning composition.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: November 7, 2017
    Assignee: Ecolab USA Inc.
    Inventors: Daniel E. Pedersen, Hilina Emiru, Carter Martin Silvernail
  • Patent number: 9808462
    Abstract: The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: November 7, 2017
    Assignee: Tangent Reprofiling Limited
    Inventors: Suzanne Dilly, Gregory Stoloff, Paul Taylor
  • Patent number: 9801879
    Abstract: This invention relates to pyridazine derivatives, compositions comprising therapeutically effective amounts of those pyridazine derivatives and methods of using those derivatives or compositions in treating central nervous system (CNS) disorders with cognitive impairment that are responsive to agonists of ?5 subunit containing GABAA receptor, e.g., age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia and cancer-therapy-related cognitive impairment.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: October 31, 2017
    Assignee: AGENEBIO, INC.
    Inventor: John A. Lowe, III
  • Patent number: 9790180
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: October 17, 2017
    Assignee: REGENACY PHARMACEUTICALS, LLC
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Patent number: 9775348
    Abstract: The present invention relates to a composition comprising at least a sesterterpene for use as medicament like antibiotic or antifungal. Furthermore, the present invention relates to the use of at least a sesterterpene for increasing, assisting and/or enhancing the bacteriostatic and/or bactericidal activity of an antibiotic or the fungicidal activity of an antifungal compound.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: October 3, 2017
    Assignee: RODE PHARMA S.R.L.
    Inventors: Luigi Amelotti, Lorenzo Secondini
  • Patent number: 9775821
    Abstract: Compositions for the treatment of shock, autodigestion, multi-organ failure, intestinal ischemia, or intestinal hypoperfusion are provided.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: October 3, 2017
    Assignee: Leading BioSciences, Inc.
    Inventors: Thomas Hallam, Robin Jackman, John Rodenrys